GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioNexus Gene Lab Corp (NAS:BGLC) » Definitions » EV-to-FCF

BGLC (BioNexus Gene Lab) EV-to-FCF : -0.90 (As of Mar. 16, 2025)


View and export this data going back to 2020. Start your Free Trial

What is BioNexus Gene Lab EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioNexus Gene Lab's Enterprise Value is $2.38 Mil. BioNexus Gene Lab's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.65 Mil. Therefore, BioNexus Gene Lab's EV-to-FCF for today is -0.90.

The historical rank and industry rank for BioNexus Gene Lab's EV-to-FCF or its related term are showing as below:

BGLC' s EV-to-FCF Range Over the Past 10 Years
Min: -1644.49   Med: 86.56   Max: 60440.51
Current: -0.9

During the past 6 years, the highest EV-to-FCF of BioNexus Gene Lab was 60440.51. The lowest was -1644.49. And the median was 86.56.

BGLC's EV-to-FCF is ranked worse than
100% of 867 companies
in the Chemicals industry
Industry Median: 21.54 vs BGLC: -0.90

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-16), BioNexus Gene Lab's stock price is $0.35. BioNexus Gene Lab's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.072. Therefore, BioNexus Gene Lab's PE Ratio (TTM) for today is At Loss.


BioNexus Gene Lab EV-to-FCF Historical Data

The historical data trend for BioNexus Gene Lab's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNexus Gene Lab EV-to-FCF Chart

BioNexus Gene Lab Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - 2,985.75 60,440.51 327.26 -2.46

BioNexus Gene Lab Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.01 -2.46 -4.87 -1.59 -1.54

Competitive Comparison of BioNexus Gene Lab's EV-to-FCF

For the Specialty Chemicals subindustry, BioNexus Gene Lab's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioNexus Gene Lab's EV-to-FCF Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where BioNexus Gene Lab's EV-to-FCF falls into.



BioNexus Gene Lab EV-to-FCF Calculation

BioNexus Gene Lab's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2.378/-2.651
=-0.90

BioNexus Gene Lab's current Enterprise Value is $2.38 Mil.
BioNexus Gene Lab's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioNexus Gene Lab  (NAS:BGLC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

BioNexus Gene Lab's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.35/-0.072
=At Loss

BioNexus Gene Lab's share price for today is $0.35.
BioNexus Gene Lab's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.072.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


BioNexus Gene Lab EV-to-FCF Related Terms

Thank you for viewing the detailed overview of BioNexus Gene Lab's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioNexus Gene Lab Business Description

Traded in Other Exchanges
N/A
Address
No. 8 Jalan Kerinchi, The Vertical Business Suite II, Unit 02, Level 10, Tower B, Avenue 3, Bangar South, Kuala Lumpur, SGR, MYS, 59200
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
Executives
Chak Hua Yew director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yeat Min Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Teng Fook Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chee Keong Yap director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Boon Teong Teoh director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Yee Meng Wong director, officer: President 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Wei Li Leong officer: Chief Financial Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chai Ping Lin director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Tai Tan Liong director, officer: Chief Operating Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Sook Keng Yeoh director, officer: Chief Executive Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200

BioNexus Gene Lab Headlines

From GuruFocus